Abstract. We examined spinal cords of neurodegenerative disease patients and controls living on the Island of Guam and in the continental United States. These patients had pathologically confirmed parkinsonism dementia-complex (PDC) with or without amyotrophic lateral sclerosis (ALS), or Alzheimer disease (AD), respectively. Nearly all of the spinal cords examined from both groups of patients contained neurofibrillary tangles (NFT). The immunohistochemical profile of these NFTs indicates that they are composed of hyperphosphorylated tau protein like their counterparts in the brains of these patients. Western blot analysis confirmed this by revealing that sarcosyl insoluble tau in spinal cord extracts from patients with NFTs exhibited the presence of all 6 tau isoforms similar to that from AD and ALS/PDC cortical gray matter.
INTRODUCTION
There is a high incidence of Parkinsonism-dementia complex (PDC) and amyotrophic lateral sclerosis (ALS) in the Chamorro population living on Guam and Rota in the Mariana Islands (1, 2) , and although Guam PDC is characterized neuropathologically by widespread and abundant tau immunoreactive neurofibrillary tangles (NFTs) throughout the brain, a subset of cases also show accumulations of A␤-rich amyloid plaques and ␣-synuclein-positive Lewy bodies (1) (2) (3) (4) (5) . NFTs in Guam PDC are formed by paired helical filaments (PHFs) composed of hyperphosphorylated tau (PHFtau) that are nearly indistinguishable from the PHFs in classic Alzheimer disease (AD), although the distribution of NFTs differs in PDC compared to AD (1-3, 6, 7) . While NFTs were thought to be virtually absent in the AD spinal cord, in contrast to the spinal cords of patients with Guam PDC or ALS and PDC (ALS/PDC) (8) (9) (10) (11) (12) , a recent immunohistochemical study demonstrated that tau-positive NFTs occur in a subset of AD spinal cords (13) . However, there are no NFTs in the spinal cord of ALS patients outside of Guam (8-10, 14, 15) . Since mechanisms of tangle formation in ALS/PDC and AD are not completely understood, and the tau epitope profile of AD spinal cord NFTs compared to that of spinal cord NFTs in Chamorro ALS/PDC patients has not been characterized, we conducted studies to address this question. Based on data reported here, we conclude that spinal cord NFTs in AD and Guam ALS/PDC share similar tau epitopes, and that the Western blot profile of insoluble tau in the AD spinal cord is similar to that seen in AD and ALS/PDC brains.
MATERIALS AND METHODS
Spinal cords from 31 patients were used in this study. Among them were 9 Chamorros, the indigenous inhabitants of Guam, 1 Filipino, and 2 Caucasians who lived on Guam for 43, 26 , and 20 yr, respectively. In addition 19 spinal cords of patients from the continental USA (2 African Americans and 17 Caucasians) with AD or one of its variants were examined. Six of these 19 spinal cords were used for biochemical studies. All 19 spinal cords were used for histochemical studies. Demographic information of the patients in this study as well as the levels of spinal cords studied are listed in Table 1 .
Biochemistry
Six frozen spinal cord samples from AD patients of the continental USA obtained during the autopsy from lumbar and cervical regions were used to characterize the distribution of pathological tau (PHFtau). Sarcosyl insoluble tau was extracted as described previously (16) . Sarcosyl insoluble fractions containing PHFtau were purified as described elsewhere (17) . Samples were resolved on 7.5% gels and transferred onto nitrocellulose membrane for immunoblotting with different phosphorylationindependent and phosphorylation-dependent antibodies against tau (Table 2) . For tau phosphoepitope characterization, preparations from different spinal cord samples were mixed together to obtain an insoluble pool of PHFtau. To determine tau isoforms composition, PHFtau preparations from spinal cord were subjected to dephosphorylation with E. coli alkaline phosphatase and resolved on 7.5% gel along with PHFtau samples extracted from AD frontal cortex gray matter. A mixture of the 6 human tau isoforms was used as a standard. PHFtau fraction from each gray matter (GM) and spinal cord (SC) sample was purified as described, resolved on 7.5% gel, and transferred onto nitrocellulose replica for immunoblotting with a phosphorylation-dependent MAB PHF1. HRP-conjugated antimouse IgG was used as a detection antibody. C ϭ cervical region; L ϭ lumbar region. B: PHF-tau phospho-epitope screening in spinal cord. Nondephosphorylated samples from 5 AD spinal cord samples were mixed together to form insoluble tau pool, resolved on 7.5% gel, and transferred onto nitrocellulose membrane (SC) along with the PHFtau preparation from AD frontal cortex gray matter (GM) for immunoblot analysis with different tau antibodies. Each template of 2 samples was blotted with phosphorylation-dependent anti-tau antibodies: AP422 (Ser 422), T3P (Ser 396), PHF1 (Ser 396/404), PHF6 (Thre 231), 12E8 (Ser 262). C: Tau isoform composition in spinal cord. PHFtau preparations from AD frontal cortex GM and SC were subjected to dephosphorylation (ϩ) with E. coli alkaline phosphatase and resolved on 7.5% gel along with nondephosphorylation samples (Ϫ). Six isoform recombinant tau mixture was used as a standard (Rt). 
* Lived more than 20 years on Guam. ** Lived 43 years on Gau. *** Lived 26 years on Guam. Abbreviations: AD ϭ Alzheimer disease; ALS ϭ amyotrophic lateral sclerosis; C ϭ cervical spinal cord; DS ϭ Down syndrome; FAD (PS2) ϭ Familial Alzheimer disease with a mutation in the PS2 gene, also known as Volga Germans; F ϭ female; LB ϭ Lewy body; LBv ϭ Lewy body variant; L ϭ lumber spinal cord; M ϭ male; PD ϭ Parkinson disease; PDC ϭ parkinsonism/ dementia complex; T ϭ thoracic spinal cord; ϩ ϭ tissue of these patients was used for immunoblotting. Abbreviations: aa ϭ amino acids; asc ϭ ascites; FA ϭ formic acid; MW ϭ microwaving; Pϩ ϭ phosphorylated; PϪ ϭ nonphosphorylated; Pi ϭ phosphate-independent. ethanol containing 150 mM sodium chloride (36) . All spinal cords were embedded in paraffin and cut into 6-m-thick sections. The tissue sections were stained with H&E, and thioflavin S (thioS) staining was carried out according to Guntern et al (37) and evaluated by epifluorescence using a FITC filter set (excitation 450-490 nm, beam splitter 510 nm, emission 530 Ϯ 15). Staining with (trans, trans), -1-bromo 2, 5-bis-(3-hydroxycarbony;-4-hydroxy)styrylbenzene (BSB) was carried out as previously described (38) . Briefly, the deparaffinized tissue sections were immersed in 0.01% (200 M) BSB in 50% ethanol for 30 min. Subsequently, the sections were quickly differentiated in an aqueous saturated solution of lithium carbonate (Li 2 CO 3 ) followed by 50% ethanol. The differentiation process was monitored in the microscope and stopped by placing the sections in distilled water. The sections were coverslipped with Vectashield (Vector Laboratories, Burlingame, CA) and inspected in an epifluorescent microscope using a filter set (excitation 405 nm, beam splitter 430 nm, emission 435 nm). Immunohistochemistry was performed according to previously published protocols (7, 35) .
The antibodies used here and their specificities are listed in Table  2 (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) . Some antibodies yielded superior staining after pretreating the tissues by boiling in an unmasking solution from Vector Laboratories (12), microwaving (39) , or by treatment with formic acid (40) . These pretreatments are also listed in Table 2 . Microscopic images were obtained using a DC-330 video camera (Biovision, Exton, PA) attached to a Nikon FXA microscope (Optical Apparatus, Inc., Ardmore, PA) and the StereoInvestigator software (Micro Brightfield, Inc., Colchester, VT). The composite images were assembled in Adobe Photoshop and printed on a Fuji Pictography 3000 printer.
Electron Microscopy
Electron microscopy was performed as previously described (41) . Briefly, NFTs were first identified in DAB-stained sections and images were obtained. The sections were deparaffinized and re-embedded in Epon 812. Approximately 100-nm-thick sections were cut and stained with uranyl acetate and lead citrate. The thin sections were viewed with a Joel 1010 at 80 kV. Abbreviations: AD ϭ Alzheimer disease; ALS ϭ amyotrophic lateral sclerosis; N ϭ Normal control; PDC ϭ parkinsonismdementia-complex of Guam.
RESULTS

Biochemical Analysis of Tau Immunoreactive Lesions from Spinal Cords of Patients from the Continental USA
Western blot analysis of sarcosyl insoluble fraction from spinal cords of 6 patients from the continental USA revealed the presence of variable amounts of PHFtau in cervical and lumbar regions (Fig. 1A) . Sarcosyl insoluble tau from the spinal cord was compared with PHFtau proteins isolated from the gray matter of AD brain. Biochemical profile of PHFtau in these samples resembled the banding pattern of PHFtau from cortical gray matter of AD brain presented with major triplet tau proteins (69, 64, and 55 kD), although the presence of lower band of 55 kD was far less obvious in spinal cord PHFtau samples. We also analyzed the presence of tau phosphoepitopes in PHFtau samples from the spinal cord using phosphorylation-dependent antibodies against tau (Fig. 1B) . PHFtau isoforms from spinal cord were hyperphosphorylated at similar epitopes as AD cortical PHFtau when monitored by phosphorylation dependent antibodies against tau (Table 2) . Finally, dephosphorylated PHFtau proteins from spinal cord exhibited an electrophoretic mobility similar to AD PHFtau, including all 6 brain tau isoforms that migrated with the 6 recombinant human tau isoforms (Fig. 1C) .
Neurofibrillary Lesions in the Spinal Cords of Patients from Guam and the Continental USA
Spinal cord sections of patients with ALS, ALS/PDC, PDC, AD, and normal control Chamorros without neurological disorder were probed with a panel of well-characterized anti-tau antibodies, an antibody to ubiquitin, as well as 2 fluorescent dyes that bind to PHFtau. Neurofibrillary lesions (NFL), i.e. neurofibrillary tangles (NFTs), pretangles, tangle like neuronal inclusions, and neuropil threads were found in all spinal cords of the Guamanian patients studied, although they were rare in the AD and control patients. All 9 well-characterized anti-tau antibodies to epitopes spanning the entire length of the tau molecule used in this study immunodecorated NFLs in these patients. Table 3 and Figure 2 summarize these results.
Patient 5, a Filipino, had lived on Guam for 43 yr and had pathologically confirmed PDC with an ALS component and clinically observed supranuclear palsy. An average of 24.66 NFLs per spinal cord section were observed in this patient who had the largest number of NFLs encountered in all spinal cords examined in this study.
All but 1 of the AD spinal cords of patients from the continental USA had NFLs. Epitopes located in the amino terminal, the mid-portion, and the carboxy terminal of the tau molecule were immunodecorated by the anti-tau antibodies used to probe these tissues. A detailed account of these lesions is given in Figure 3 .
In the spinal cords of subjects from both Guam and the continental USA, the NFLs were most frequently encountered in the substantia intermedia of the spinal cords. They also occurred in the lateral and dorsal horns as well as in the ventral horns. In the latter, they were more often seen in small neurons and less frequently in anterior horn cells. Some NFLs were also observed in ectopic neurons. Besides typical NFTs with a striated appearance, neuronal inclusions with a spotted staining pattern were also observed with anti-tau antibodies. Lesions showing this spotted staining pattern were thioS-and BSB-negative and thus might present a pretangle stage in spinal cord neurons. Neuropil threads were found in many spinal cord sections with or without other NFLs present. Figure  4 shows representative samples of these lesions.
The monoclonal antibody (MAB) to ubiquitin labeled only a fraction of the NFLs described above. It also immunostained occasional dilated processes and showed a dotted staining pattern in some neurons that was distinct from the tau immunoreactive lesions described above (Fig. 6A-C) .
The spinal cord sections of the patients from Guam were also probed with antibodies to highly phosphorylated (RMO24) and nonphosphorylated neurofilament proteins (NFPs) (RMDO20). There were small RMO24-positive globules found in the anterior horns of a few patients (Fig. 6D) . However, large spheroids were not immunostained with either antibody to NFPs. Also, neither neurofilament nor ubiquitin immunoreactive neuronal inclusions were observed. Syn303, a MAB to ␣-synuclein, was used to probe the spinal cord section from the Guamanian patients, but no Lewy bodies or other ␣-synuclein-positive lesions were found.
Tau immunoreactive astroglial cell bodies and their endfeet were found in some Guam and continental USA subjects, but in patients 1-3, 7, 10, 22, and 28, tau immunoreactive glia were rare. In contrast, in 2 Guamanian patients (patients 5 and 9), a large amount of tau-positive glia was present (Fig. 6E, F) . All tau antibodies used in this study immunostained at least some glia and PHF6 and AT180 immunostained more glial cells than the other antitau antibodies. Electron micrographs of spinal cord NFTs of a Guamanian PDC patient obtained at a magnification of ϫ5,000 showed that they were composed of fibrils (Fig.  7) . Amorphous material in irregular patches was dispersed among the fibrils.
DISCUSSION
In this study we show that tau-positive NFTs and related NFLs in the spinal cord and brains of AD patients from the continental USA are composed of all 6 brain tau isoforms that are similar in molecular weight and epitope profile. In a previous study we demonstrated that NFTs from the brains of Guamanian ALS/PDC patients resemble AD NFTs (7). Although frozen spinal cord tissue from the Guamanian patients was not available, the epitope analysis indicates that NFTs from the spinal cord of these patients are composed of the same hyperphosphorylated tau isoforms as their counterparts in the brains and spinal cords of AD patients from the continental USA. This shows that diverse neuronal populations in the brain and spinal cord of patients with distinct tauopathies as well as normal elderly Chamorros are selectively vulnerable to the molecular mechanisms leading to NFT formation (42) . Similarly, transgenic mice that overexpress the smallest isoform of human tau form age-dependent NFTs in their brains and tau-positive inclusions in spinal cord neurons (43, 44) . Thus, since these transgenic mice model authentic neurofibrillary tau pathology in spinal cords of patients with diverse tauopathies, they open new avenues for developing therapies for the prevention or interruption of NFT formation in a variety of human neurodegenerative diseases.
Indeed, a number of other transgenic mice exist that overexpress wild type mutant tau and develop a neurodegenerative disease phenotype of variable severity, especially in spinal cord (45) (46) (47) (48) , and that may enable investigations of the biological and pathological significance of biochemically and morphologically distinct forms of tau lesions. For example, differences in the ultrastructure of the abnormal tau filaments in NFTs have been seen in AD versus Guam PDC (3, 7, 13, 49) as well as in other tauopathies (47) , although a recent mutant tau transgenic fly developed brain degeneration and tau aggregates but not NFTs or abnormal tau filaments (50) , implying that at least in the case of mutant tau in the fly, nonfilamentous tau protein aggregates may be toxic to neurons. However, this may not be true in all tauopathies, and clearly motor neurons degenerate in ALS outside Guam in the absence of NFTs (1, 3) . While the reasons for these differences between ALS within and outside Guam are not known, it will be important for the development of therapies for tauopathies to elucidate what components of the various tau lesions are the most relevant for ameliorating the neurodegenerative consequences of the progressive accumulation of tau pathologies.
